The discovery of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) has changed the field of gene editing. These repeated sequences are found in bacterial genomes with short DNA sequences derived from viruses which have infected the bacteria interspaced. These virally derived sequences can make short RNA sequences which can hybridize with specific viral DNA and target a nuclease, such as Cas9, to the viral sequence. So, if the bacteria are infected by this virus again, Cas9 can be directed to cleave the specific viral sequence and so inactivate the virus. By careful design of the RNA sequence the system can be used to specifically cut DNA virtually anywhere, including in living human and other mammalian cells. This allows inexpensive gene editing with unprecedented ease, and much effort is going into refining the Cas9 enzymes and their relatives for use in mammalian systems.
Several varieties of Cas9 have been studied and there appear to be several o ther related enzymes with similar properties in bacteria. Two Cas9 homologs include Streptococcus pyogense and Staphylococcus aureus. The S. pyogenes protein is rather large at 1,368 amino acids, ~160kDa, so the corresponding DNA is also rather large at about 4.2 kb. Staphylococcus aureus is significantly smaller, at about 3 kb producing a protein 124 kDa. Thus presents less problems when packaged into vectors. Our antibody is a mouse monoclonal raised against the C-terminal 251 amino acids of of the Staphylococcus aureus protein and binds this protein transfected into cells on western blots and in immunocytochemistry.